Literature DB >> 10074183

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

E J Verschoor1, P Mooij, H Oostermeijer, M van der Kolk, P ten Haaft, B Verstrepen, Y Sun, B Morein, L Akerblom, D H Fuller, S W Barnett, J L Heeney.   

Abstract

The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-gamma) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the fourth immunization, and the rgp120/MF59 group generated both IFN-gamma and interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-gamma (type 1-like), and IL-4 responses that peaked after the second immunization. To determine which type of immune responses correlated with protection from infection, all animals were challenged intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were completely protected from infection. In other subunit vaccinees there was evidence by multiple assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of potent type 1- as well as type 2-like T-helper responses induced the most-effective immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074183      PMCID: PMC104093     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  In vivo and in vitro induction of IL-6 by Quillaja saponaria molina triterpenoid formulations.

Authors:  S Behboudi; B Morein; M Villacres-Eriksson
Journal:  Cytokine       Date:  1997-09       Impact factor: 3.861

2.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

3.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

4.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

Authors:  C Bruck; C Thiriart; L Fabry; M Francotte; P Pala; O Van Opstal; J Culp; M Rosenberg; M De Wilde; P Heidt; J Heeney
Journal:  Vaccine       Date:  1994-09       Impact factor: 3.641

6.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

Authors:  K S Steimer; C J Scandella; P V Skiles; N L Haigwood
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

7.  Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine.

Authors:  P Putkonen; E Björling; L Akerblom; R Thorstensson; K Lövgren; L Benthin; F Chiodi; B Morein; G Biberfeld; E Norrby
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-06

8.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.

Authors:  J P Valensi; J R Carlson; G A Van Nest
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

10.  Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells.

Authors:  J L Heeney; C van Els; P de Vries; P ten Haaft; N Otting; W Koornstra; J Boes; R Dubbes; H Niphuis; M Dings; M Cranage; S Norley; M Jonker; R E Bontrop; A Osterhaus
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  15 in total

1.  Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine.

Authors:  Xiao-Ju Guan; Xiao-Jun Guan; Yu-Zhang Wu; Zheng-Cai Jia; Tong-Dong Shi; Yan Tang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.

Authors:  P Mooij; W M Bogers; H Oostermeijer; W Koornstra; P J Ten Haaft; B E Verstrepen; G Van Der Auwera; J L Heeney
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Authors:  A M González; T V Nguyen; M S P Azevedo; K Jeong; F Agarib; C Iosef; K Chang; K Lovgren-Bengtsson; B Morein; L J Saif
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

6.  Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.

Authors:  Ilnour Ourmanov; Takeo Kuwata; Robert Goeken; Simoy Goldstein; Ranjani Iyengar; Alicia Buckler-White; Bernard Lafont; Vanessa M Hirsch
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

Review 7.  The ABC of clinical and experimental adjuvants--a brief overview.

Authors:  Richard Brunner; Erika Jensen-Jarolim; Isabella Pali-Schöll
Journal:  Immunol Lett       Date:  2009-11-04       Impact factor: 3.685

8.  Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Authors:  Petra Mooij; Ivonne G Nieuwenhuis; Christiaan J Knoop; Robert W Doms; Willy M J M Bogers; Peter J F Ten Haaft; Henk Niphuis; Wim Koornstra; Kurt Bieler; Josef Köstler; Brør Morein; Aurelio Cafaro; Barbara Ensoli; Ralf Wagner; Jonathan L Heeney
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.

Authors:  Colin Havenar-Daughton; Diane G Carnathan; Alba Torrents de la Peña; Matthias Pauthner; Bryan Briney; Samantha M Reiss; Jennifer S Wood; Kirti Kaushik; Marit J van Gils; Sandy L Rosales; Patricia van der Woude; Michela Locci; Khoa M Le; Steven W de Taeye; Devin Sok; Ata Ur Rasheed Mohammed; Jessica Huang; Sanjeev Gumber; AnaPatricia Garcia; Sudhir P Kasturi; Bali Pulendran; John P Moore; Rafi Ahmed; Grégory Seumois; Dennis R Burton; Rogier W Sanders; Guido Silvestri; Shane Crotty
Journal:  Cell Rep       Date:  2016-11-22       Impact factor: 9.423

10.  Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Klara Sirokman; Avishek Nandi; Karin Hartog; Ying Lian; Anthony R Geonnotti; David Montefiori; Michael Franti; Grégoire Martin; Andrea Carfi; Pascal Kessler; Loïc Martin; Indresh K Srivastava; Susan W Barnett
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.